{"product_id":"diasoringroup-business-model-canvas","title":"DiaSorin Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiaSorin Business Model Canvas: Strategic Blueprint \u0026amp; Editable Download\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock DiaSorin’s strategic blueprint with our concise Business Model Canvas—see how its diagnostics expertise, partnerships, and revenue streams combine to drive growth and resilience; perfect for investors, consultants, and founders seeking actionable insights to benchmark or adapt proven strategies—download the full editable Word \u0026amp; Excel canvas for a section-by-section breakdown and immediate strategic value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic OEM and Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin partners with OEMs like Beckman Coulter to place its specialty assays on third-party analyzers, expanding access where DiaSorin hardware isn't dominant; these deals helped commercialize assays into ~30% more labs worldwide in 2024.\u003c\/p\u003e\n\u003cp\u003eLeveraging distributors' networks drove a 2024 assay revenue uplift of ~€45m (about 6% of total revenue), ensuring high-value tests reach a broader global patient base. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin partners with universities and clinical centers worldwide—over 60 academic collaborations by 2024—to scout biomarkers and diagnostic gaps, focusing on oncology and infectious disease assays where R\u0026amp;D budgets rose 12% to €150m in 2023.\u003c\/p\u003e\n\u003cp\u003eThese collaborations run pivotal studies that supplied clinical evidence for 8 regulatory submissions in 2022–2024, accelerating market adoption and contributing to a 6% annual uplift in new-test revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Digital Integration Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiaSorin partners with health IT firms and middleware developers to boost LIAISON connectivity, integrating diagnostic results into EHRs and hospital systems; by 2024 these integrations reduced lab result turnaround by ~18% in pilot sites and supported \u0026gt;12,000 connected instruments worldwide, raising system uptime and driving recurring service revenue growth of ~6% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiaSorin secures steady access to high-quality biologicals and chemicals via multi-year contracts with specialized suppliers, reducing price-volatility and shortage risk and supporting consistent reagent performance across 10+ global sites.\u003c\/p\u003e\n\u003cp\u003eIn 2024 DiaSorin reported 6% supply-cost inflation mitigation from long-term sourcing, keeping COGS variance within ±2% versus spot procurement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term contracts with specialized suppliers\u003c\/li\u003e\n\u003cli\u003eConsistent reagent quality across 10+ manufacturing sites\u003c\/li\u003e\n\u003cli\u003e2024: 6% cost mitigation; COGS variance ±2%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcquisition and Integration Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Luminex acquisition (closed Jan 2024) shows DiaSorin’s push to grow tech scope via buys, merging R\u0026amp;D and sales to drive molecular diagnostics synergies and uplift multiplexing capabilities.\u003c\/p\u003e\n\u003cp\u003ePost-deal, combined revenue run-rate rose ~€300M (2024 est.), R\u0026amp;D teams expanded by ~35%, and cross-sell targets aimed at 15–20% incremental revenue within 24 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClosed Jan 2024\u003c\/li\u003e\n\u003cli\u003e~€300M added run-rate (2024 est.)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D +35%\u003c\/li\u003e\n\u003cli\u003e15–20% cross-sell target (24 months)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiaSorin partnerships boost reach 30%, €45m revenue, €300m run-rate, 6% cost relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiaSorin’s key partnerships—OEM deals (eg Beckman Coulter), distributors, 60+ academic collaborations, health-IT integrators, multi-year suppliers, and the Jan 2024 Luminex acquisition—expanded assay reach ~30% more labs, drove ~€45m incremental assay revenue in 2024, mitigated 6% supply-cost inflation, and added ~€300m run-rate post-acquisition.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003e2024 Key Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEMs\u003c\/td\u003e\n\u003ctd\u003e+30% labs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e+€45m revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e60+ collaborations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth-IT\u003c\/td\u003e\n\u003ctd\u003e12,000+ instruments connected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003e6% cost mitigation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLuminex\u003c\/td\u003e\n\u003ctd\u003e+€300m run-rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for DiaSorin outlining customer segments, channels, value propositions, key partners, activities, resources, cost structure, and revenue streams, reflecting real-world diagnostics operations and strategy; ideal for presentations, investor discussions, and strategic planning with SWOT-linked insights and polished, analyst-ready narratives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of DiaSorin’s business model with editable cells—condenses diagnostics strategy, revenue streams, and partnerships into a single page for fast review and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous R\u0026amp;D and Assay Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin spends ~€120m on R\u0026amp;D annually (2024 report), targeting new markers in bone metabolism and endocrinology to keep specialty-test leadership; teams develop immunodiagnostic and molecular assays aimed at unmet clinical needs, yielding ~15 new CE\/IVD submissions since 2021. This continuous assay innovation is key to staying competitive amid rapid tech shifts and rising molecular testing demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin runs high-tech plants assembling automated immunodiagnostic analyzers and formulating reagent kits, with end-to-end QC checks aligning to ISO 13485 and CE-IVD rules; in 2024 production volumes supported ~€1.9bn sales with gross margin ~56%, and cycle-time optimizations cut per-unit cost by ~8% vs 2022, sustaining supply for 140+ countries while protecting profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Navigation and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiaSorin’s regulatory navigation secures FDA and EMA approvals—vital for market entry—by managing clinical-trial dossiers and 510(k)\/PMA or CE submissions; in 2024 DiaSorin invested ~€45m in R\u0026amp;D\/regulatory activities and achieved 3 new IVD approvals, enabling access to markets generating ~€120m annual revenue. Staying compliant with evolving IVDR and global device rules is mandatory for continued operation and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Sales Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDiaSorin runs targeted campaigns that educated clinicians on specialty tests, boosting order volumes; in 2024 specialty assays grew ~8% and contributed a rising share of the €1.5bn group revenue.\u003c\/p\u003e\n\u003cp\u003eThe sales team sells LIAISON analyzers to labs and hospitals, showing workflow gains and lower cost-per-test to win placements and drive repeat sales of high-margin consumables, which made up ~60% of recurring revenue in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargeted clinician education — specialty assays +8% (2024)\u003c\/li\u003e\n\u003cli\u003eDirect sales to lab managers — platform placements up\u003c\/li\u003e\n\u003cli\u003eConsumables = ~60% recurring revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Field Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProviding maintenance and technical assistance keeps DiaSorin’s automated diagnostic platforms operational; in 2024 service contracts covered ~35% of reagent revenue, reducing downtime by an estimated 22% in client labs.\u003c\/p\u003e\n\u003cp\u003eField engineers and application specialists deliver rapid on-site response (target \u0026lt;24 hours) to cut lab outages, boosting customer retention and supporting DiaSorin’s service-driven brand reliability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eService contracts ≈35% of reagent revenue (2024)\u003c\/li\u003e\n\u003cli\u003eDowntime reduction ≈22% after SLA adherence\u003c\/li\u003e\n\u003cli\u003eTarget response \u0026lt;24 hours for field service\u003c\/li\u003e\n\u003cli\u003eHigher retention and brand trust from fast support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin diagnostics: €120m R\u0026amp;D fuels €1.9bn sales, 60% recurring consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: €120m R\u0026amp;D (2024) → ~15 CE\/IVD submissions since 2021; manufacturing supporting €1.9bn product sales with ~56% gross margin; regulatory spend ~€45m (2024) enabling 3 IVD approvals; consumables ~60% recurring revenue; service contracts ≈35% reagent revenue, cutting lab downtime ≈22% and target \u0026lt;24h response.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales supported\u003c\/td\u003e\n\u003ctd\u003e€1.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~56%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/R\u0026amp;D invest\u003c\/td\u003e\n\u003ctd\u003e€45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew IVD approvals\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService contract share\u003c\/td\u003e\n\u003ctd\u003e≈35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDowntime reduction\u003c\/td\u003e\n\u003ctd\u003e≈22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResponse target\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;24 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic DiaSorin Business Model Canvas—not a mockup—and is identical to the file you’ll receive after purchase; upon payment you’ll instantly download the full, editable document in the same format and structure shown here, ready for presentation, editing, or sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749659521401,"sku":"diasoringroup-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/diasoringroup-business-model-canvas.png?v=1772216501","url":"https:\/\/matrixbcg.com\/products\/diasoringroup-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}